Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11947206 | 0.92 | HRH4 (0.35) | ARG1ARG2HRH4HRH3KDM4E | |
| SCHEMBL20812158 | 0.90 | HRH4 (0.37) | ARG1ARG2HRH4HRH3KDM4E | |
| SCHEMBL14509576 | 0.90 | HRH4 (0.37) | ARG1ARG2HRH4HRH3KDM4E | |
| SCHEMBL20812165 | 0.90 | HRH4 (0.37) | ARG1ARG2HRH4HRH3KDM4E | |
| SCHEMBL13884349 | 0.90 | HRH4 (0.37) | ARG1ARG2HRH4HRH3KDM4E | |
| SCHEMBL10226405 | 0.90 | HRH4 (0.37) | ARG1ARG2HRH4HRH3KDM4E | |
| SCHEMBL13884361 | 0.90 | HRH4 (0.37) | ARG1ARG2HRH4HRH3KDM4E | |
| SCHEMBL841264 | 0.83 | ARG1 (0.34) | ARG1ARG2 | |
| SCHEMBL23101977 | 0.80 | ARG1 (0.38) | ARG1ARG2HRH4HRH3KDM4E | |
| SCHEMBL21350501 | 0.80 | ARG1 (0.31) | ARG1ARG2HRH4HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024076672-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220402950-A1 | SUBSTITUTED BENZIMIDAZOLES AS PAD4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2022-12-22 | — | — | US | disclosed |
| US-20220168433-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220047709-A1 | DEGRADERS OF WEE1 KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | US | disclosed |
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| US-20210382058-A1 | PATIENT SELECTION FOR TREATMENT OF MYC POSITIVE CANCERS WITH INDENOISOQUINOLINES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-09 | — | — | US | disclosed |
| US-11124485-B2 | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-09-21 | — | — | US | disclosed |
| US-20210198280-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7598247-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| US-7449486-B2 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449486-B2 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080182992-A1 | Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents | ARRAY BIOPHARMA, INC. | 2008-07-31 | — | — | US | disclosed |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198280-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | ARG1 4059/4885ARG2 4025/4885HRH4 3725/4885 |
| US-20220168433-A1 | PROGRAMMABLE POLYMERIC DRUGS | CHRM1, PBRM1, CHRM2 | ARG1 343/4885ARG2 603/4885HRH4 981/4885 |
| US-20090048300-A1 | Heterocyclic Compounds | HDAC1, HDAC3, HDAC11 | ARG1 3099/4885ARG2 1187/4885HRH4 282/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | ARG1 1688/4885ARG2 2571/4885HRH4 107/4885 |
| US-20220402950-A1 | SUBSTITUTED BENZIMIDAZOLES AS PAD4 INHIBITORS | PADI4, PADI1, PADI6 | ARG1 286/4885ARG2 216/4885HRH4 1624/4885 |
| US-20080182992-A1 | Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents | KIF5B, KIF2C, KIFC1 | ARG1 2596/4885ARG2 3177/4885HRH4 3855/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | ARG1 1688/4885ARG2 2571/4885HRH4 107/4885 |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | ARG1 12/4885ARG2 101/4885HRH4 17/4885 |
| US-20220047709-A1 | DEGRADERS OF WEE1 KINASE | WEE1, WEE2, PPME1 | ARG1 3964/4885ARG2 3728/4885HRH4 2655/4885 |
| US-11124485-B2 | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage | DPYD, DUT, TYMP | ARG1 4078/4885ARG2 2736/4885HRH4 4771/4885 |
| US-11247984-B2 | Uracil containing compounds | UNG, DPYD, DUT | ARG1 4085/4885ARG2 3540/4885HRH4 4564/4885 |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | ARG1 12/4885ARG2 101/4885HRH4 17/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | ARG1 15/4885ARG2 127/4885HRH4 19/4885 |
| US-20210382058-A1 | PATIENT SELECTION FOR TREATMENT OF MYC POSITIVE CANCERS WITH INDENOISOQUINOLINES | MYC, MYCBP, MYCBP2 | ARG1 4018/4885ARG2 3940/4885HRH4 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.